Pharvaris NV’s stock price plummeted after a $175 million public offering, but the company aims to use the funds to accelerate its drug development pipeline and potentially turn its financial metrics around.

Pharvaris NV, a clinical-stage biopharmaceutical company, faces financial challenges and stock volatility as it prepares to present clinical data at an upcoming conference.